|
EP3187182B1
(en)
|
2008-09-02 |
2021-03-03 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
|
|
JP5694941B2
(ja)
|
2008-10-17 |
2015-04-01 |
シーマベイ セラピューティクス，インコーポレイティド |
小型高密度ｌｄｌ粒子を減少させる方法
|
|
CN107233337A
(zh)
|
2009-04-29 |
2017-10-10 |
阿马里纳药物爱尔兰有限公司 |
含有epa和心血管剂的药物组合物以及使用其的方法
|
|
MX377553B
(es)
|
2009-04-29 |
2025-03-10 |
Amarin Pharma Inc |
Composicion farmaceutica estable y metodos de uso de la misma.
|
|
BRPI1011883A2
(pt)
|
2009-06-15 |
2016-09-13 |
Amarin Pharma Inc |
uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina
|
|
NZ599061A
(en)
|
2009-09-23 |
2014-05-30 |
Amarin Pharmaceuticals Ie Ltd |
Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
|
|
WO2011140441A2
(en)
|
2010-05-06 |
2011-11-10 |
Children's Hospital Medical Center |
Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
|
|
NZ744990A
(en)
|
2010-11-29 |
2019-10-25 |
Amarin Pharmaceuticals Ie Ltd |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
|
US11712429B2
(en)
|
2010-11-29 |
2023-08-01 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
|
WO2013070735A1
(en)
|
2011-11-07 |
2013-05-16 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
|
US11291643B2
(en)
|
2011-11-07 |
2022-04-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
|
EP2800469B1
(en)
|
2012-01-06 |
2021-08-25 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
|
|
US9603826B2
(en)
|
2012-06-29 |
2017-03-28 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
|
|
WO2014074552A2
(en)
|
2012-11-06 |
2014-05-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
|
|
US9814733B2
(en)
*
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
|
US20140187633A1
(en)
|
2012-12-31 |
2014-07-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
|
|
US9452151B2
(en)
|
2013-02-06 |
2016-09-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing apolipoprotein C-III
|
|
US9624492B2
(en)
|
2013-02-13 |
2017-04-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
|
|
US9662307B2
(en)
|
2013-02-19 |
2017-05-30 |
The Regents Of The University Of Colorado |
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
|
|
US9283201B2
(en)
|
2013-03-14 |
2016-03-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating or preventing obesity in a subject in need thereof
|
|
US20140271841A1
(en)
|
2013-03-15 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
|
|
US10966968B2
(en)
|
2013-06-06 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
|
|
US20150065572A1
(en)
|
2013-09-04 |
2015-03-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing prostate cancer
|
|
US9585859B2
(en)
|
2013-10-10 |
2017-03-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
|
US10272058B2
(en)
|
2014-03-20 |
2019-04-30 |
Cymabay Therapeutics, Inc. |
Treatment of intrahepatic cholestatic diseases
|
|
ES2701094T3
(es)
|
2014-03-20 |
2019-02-20 |
Cymabay Therapeutics Inc |
Tratamiento de enfermedades colestáticas intrahepáticas
|
|
CA2944139C
(en)
*
|
2014-04-11 |
2020-11-03 |
Cymabay Therapeutics, Inc. |
Treatment of nafld and nash
|
|
ES2860423T3
(es)
|
2014-05-28 |
2021-10-05 |
Childrens Hospital Med Ct |
Métodos y sistemas para convertir células precursoras en tejidos gástricos mediante diferenciación dirigida
|
|
US10561631B2
(en)
|
2014-06-11 |
2020-02-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing RLP-C
|
|
WO2015195662A1
(en)
|
2014-06-16 |
2015-12-23 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
|
|
CA2963704A1
(en)
|
2014-10-17 |
2016-04-21 |
Children's Hospital Medical Center |
In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
|
|
HK1248537A1
(zh)
*
|
2015-03-26 |
2018-10-19 |
T3D治疗有限责任公司 |
使用茚满乙酸衍生物治疗肝病的方法
|
|
AU2016256552B2
(en)
|
2015-04-28 |
2021-04-01 |
Pronova Biopharma Norge As |
Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis
|
|
US10940125B2
(en)
|
2015-09-18 |
2021-03-09 |
Duke University |
Methods and compositions for the treatment of steatosis-associated disorders
|
|
WO2017139708A1
(en)
|
2016-02-10 |
2017-08-17 |
Synlogic, Inc. |
Bacteria engineered to treat nonalcoholic steatohepatitis (nash)
|
|
US10406130B2
(en)
|
2016-03-15 |
2019-09-10 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
|
US12053445B2
(en)
|
2016-03-31 |
2024-08-06 |
Genfit |
Methods of treatment of cholestatic diseases
|
|
CN109415685B
(zh)
|
2016-05-05 |
2023-07-04 |
儿童医院医疗中心 |
用于体外制造胃底组织的方法和与其相关的组合物
|
|
GB201614455D0
(en)
*
|
2016-08-24 |
2016-10-05 |
Univ Oxford Innovation Ltd |
Biomarkers
|
|
SG10202104575WA
(en)
*
|
2016-11-04 |
2021-06-29 |
Childrens Hospital Med Ct |
Liver organoid compositions and methods of making and using same
|
|
US10493363B2
(en)
*
|
2016-11-09 |
2019-12-03 |
Activision Publishing, Inc. |
Reality-based video game elements
|
|
CA3045145A1
(en)
|
2016-12-05 |
2018-06-14 |
Children's Hospital Medical Center |
Colonic organoids and methods of making and using same
|
|
US12281334B2
(en)
|
2017-04-14 |
2025-04-22 |
Children's Hospital Medical Center |
Multi donor stem cell compositions and methods of making same
|
|
TWI762634B
(zh)
|
2017-05-05 |
2022-05-01 |
大陸商上海赫普化醫藥技術有限公司 |
胺基-芳基-苯甲醯胺化合物及其使用方法
|
|
US10966951B2
(en)
|
2017-05-19 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject having reduced kidney function
|
|
US10512622B2
(en)
|
2017-07-14 |
2019-12-24 |
Cymabay Therapeutics, Inc. |
Treatment of intrahepatic cholestatic diseases
|
|
JP2020533339A
(ja)
|
2017-09-13 |
2020-11-19 |
ノバルティス アーゲー |
Ｆｘｒアゴニストを含む組合せ
|
|
WO2019074793A1
(en)
|
2017-10-10 |
2019-04-18 |
Children's Hospital Medical Center |
OESOPHAGIAN TISSUE COMPOSITIONS AND / OR ORGANOIDS AND METHODS OF MAKING SAME
|
|
US11260066B2
(en)
|
2017-10-27 |
2022-03-01 |
Samyang Corporation |
Inhibiting reduction of lean body mass and inhibiting accumulation of liver fat by administering allulose
|
|
IL308604B2
(en)
|
2017-12-06 |
2025-08-01 |
Basf As |
Fatty acid derivatives for treating non-alcoholic steatohepatitis
|
|
US12379372B2
(en)
|
2017-12-21 |
2025-08-05 |
Children's Hospital Medical Center |
Digitalized human organoids and methods of using same
|
|
US11058661B2
(en)
|
2018-03-02 |
2021-07-13 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
|
|
CA3106634A1
(en)
|
2018-07-26 |
2020-01-30 |
Children's Hospital Medical Center |
Hepato-biliary-pancreatic tissues and methods of making same
|
|
CN112823012A
(zh)
|
2018-09-12 |
2021-05-18 |
儿童医院医学中心 |
用于产生造血干细胞及其衍生物的类器官组合物
|
|
MA50490A
(fr)
|
2018-09-24 |
2020-09-02 |
Amarin Pharmaceuticals Ie Ltd |
Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
|
|
MX2021005724A
(es)
*
|
2018-11-16 |
2021-07-21 |
Cymabay Therapeutics Inc |
Tratamiento combinado contra nafld y nash.
|
|
WO2020102351A1
(en)
*
|
2018-11-16 |
2020-05-22 |
Cymabay Therapeutics, Inc. |
Treatment of obesity and its complications
|
|
CN121081472A
(zh)
|
2018-12-13 |
2025-12-09 |
拓臻股份有限公司 |
一种THRβ受体激动剂化合物及其制备方法和用途
|
|
WO2020160371A1
(en)
|
2019-02-01 |
2020-08-06 |
The University Of Hong Kong |
Innervated organoid compositions and methods of making same
|
|
CA3141807A1
(en)
|
2019-05-31 |
2020-12-03 |
Children's Hospital Medical Center |
Methods of generating and expanding hematopoietic stem cells
|
|
US12534709B2
(en)
|
2019-05-31 |
2026-01-27 |
Children's Hospital Medical Center |
Shaped organoid compositions and methods of making same
|
|
CA3154488A1
(en)
|
2019-08-23 |
2021-03-04 |
Terns Pharmaceuticals, Inc. |
Thyroid hormone receptor beta agonist compounds
|
|
CA3154391A1
(en)
|
2019-09-12 |
2021-03-18 |
Terns Pharmaceuticals, Inc. |
Thyroid hormone receptor beta agonist compounds
|
|
CA3160676A1
(en)
|
2019-11-12 |
2021-05-20 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
|
|
US20210145774A1
(en)
|
2019-11-14 |
2021-05-20 |
Cymabay Therapeutics, Inc. |
Treatment of alcoholic liver disease
|
|
WO2021097034A1
(en)
|
2019-11-14 |
2021-05-20 |
Cymabay Therapeutics, Inc. |
Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases
|
|
WO2021231646A1
(en)
*
|
2020-05-13 |
2021-11-18 |
Terns Pharmaceuticals, Inc. |
Combination treatment of liver disorders
|
|
CN115884765A
(zh)
|
2020-08-26 |
2023-03-31 |
基恩菲特公司 |
用于治疗原发性胆汁性胆管炎的组合物和方法
|
|
US11986452B2
(en)
|
2021-04-21 |
2024-05-21 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of heart failure
|
|
US20240216312A1
(en)
*
|
2021-05-11 |
2024-07-04 |
Genfit |
Ppar-agonists for use in the treatment of liver failure
|